RXRX FY 2024 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$59M+34.1% YoY

Gross Profit

$14M23.1% margin

Operating Income

-$479M-814.1% margin

Net Income

-$464M-788.0% margin

EPS (Diluted)

$-1.69

Cash Flow

Operating Cash Flow

-$359M

Free Cash Flow

-$373M

Stock-Based Comp.

$82M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$414M

Stockholders' Equity

$1.0B

Cash & Equivalents

$594M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$59M	$44M	+34.1%
Gross Profit	$14M	$1M	+955.2%
Operating Income	-$479M	-$350M	-36.8%
Net Income	-$464M	-$328M	-41.3%